# Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes

> **NCT00106808** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 1440 (—)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Muraglitazar
- **DRUG:** Pioglitazone

## Key facts

- **NCT ID:** NCT00106808
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** 1440 (—)
- **Last updated:** 2010-09-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00106808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00106808, "Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00106808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*